Neuroreport 11, 2885-2888, (2000). Romieu, P., Martin-Fardon, R., & Maurice, T View abstract in PubMed Post navigationPreviousPrevious post:Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice.NextNext post:Animal models of Alzheimer’s disease and evaluation of anti-dementia drugs.Related PostsAnavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx ConferenceNovember 25, 2020Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 ConferenceNovember 6, 2020Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease DementiaOctober 15, 2020Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020
Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx ConferenceNovember 25, 2020
Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 ConferenceNovember 6, 2020
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease DementiaOctober 15, 2020
Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialSeptember 10, 2020
